Comparable stake leader
ORBIMED ADVISORS LLC
SEC ownership of Traws Pharma, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001130598.
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
32/50
Latest evidence
09 Jul 2026
- Public ticker
- TRAW on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ORBIMED ADVISORS LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
32 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ORBIMED ADVISORS LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
09 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001130598
- Issuer location
- Newtown, PA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Traws Pharma, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
32/50
Latest evidence
09 Jul 2026
13D/G
3/4/5
13F
Lead comparable stake: 12%
18 rows are not safely comparable across share classes.
13D/G row: ORBIMED ADVISORS LLC
Showing 1-8 of 50 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 12%.
32 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
12%
Ikarian Capital, LLC
10%
Alyeska Investment Group, L.P.
9.9%
Adage Capital Management, L.P.
9.1%
Jorey Chernett
6.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13D/G
3/4/5
13F
10%+ Owner · Company
|
12%
|
$3,431,754
1,876,198 shares
|
+$2,040,131 | 16 Apr 2026 |
| Ikarian Capital, LLC |
13D/G
13F
Company
|
10%
|
$1,308,164
812,524 shares
|
+$359,065 | 31 Dec 2025 |
| Alyeska Investment Group, L.P. |
13D/G
|
9.9%
|
$462,446
302,252 shares
|
$0 | 31 Dec 2024 |
| Adage Capital Management, L.P. |
13D/G
|
9.1%
|
$1,175,300
730,000 shares
|
+$644,000 | 31 Dec 2025 |
| Jorey Chernett |
13D/G
Chernett Jorey
|
6.8%
|
$668,220
543,268 shares
|
$0 | 14 Jan 2026 |
| Squadron Capital Management LLC |
13F
13D/G
Company · Squadron Master Fund LP
|
6.4%
from 13D/G
|
$936,437
511,714 shares
|
— | 31 Mar 2026 |
| PERCEPTIVE ADVISORS LLC |
13D/G
|
6.1%
|
$1,793,061
979,815 shares
|
+$170,058 | 31 Mar 2026 |
| Ayrton Capital LLC |
13D/G
|
4.3%
|
$552,125
342,935 shares
|
-$97,751 | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$1,996,415.
Buys
$1,996,415
Insiders: 2
Sells
$0
Insiders: 0
Net
+$1,996,415
Shares: +1,195,458
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 1,195,458
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 1,195,458 | 0 | $1,996,415 | $0 | +$1,996,415 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 25 reporting-owner rows connected to Traws Pharma, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
25
Largest Forms 3/4/5 holder
OrbiMed Capital GP VIII LLC
Net 12M change
+$1,996,414
Latest report
09 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| OrbiMed Capital GP VIII LLC | 10%+ Owner | $2,009,427 | +$998,207 | +99% | Filing P/S | 16 Apr 2026 |
| ORBIMED ADVISORS LLC | 10%+ Owner | $2,009,427 | +$998,207 | +99% | Filing P/S | 16 Apr 2026 |
| Viriom, Inc. | 10%+ Owner | $1,480,590 | Mixed | 03 Apr 2024 | ||
| Iain D. Dukes | Chief Executive Officer, Director | $438,092 | Mixed | 09 Jul 2026 | ||
| Nikolay Savchuk | Chief Operating Officer, Director | $385,551 | Mixed | 09 Jul 2026 | ||
| Charles D. Pauza | Chief Science Officer Virology | $296,885 | Mixed | 09 Jul 2026 | ||
| Robert Redfield | Chief Medical Officer | $291,632 | Mixed | 09 Jul 2026 | ||
| Werner Cautreels | Director | $279,608 | Mixed | 09 Jul 2026 | ||
| Steven M. Fruchtman | PRESIDENT, CHIEF EXECUTIVE OFF, Director | $98,282 | Mixed | 13 Mar 2024 | ||
| Abraham N. Oler | SVP Corp Dev & Gen Counsel | $36,818 | Mixed | 07 Feb 2022 | ||
| Charles N. Parker | Chief Financial Officer | $24,628 | Mixed | 09 Jul 2026 | ||
| Mark Patrick Guerin | Chief Financial Officer | $23,400 | Mixed | 05 Feb 2025 | ||
| Mary Teresa Shoemaker | Director | $16,107 | Mixed | 09 Jul 2026 | ||
| Jack E. Stover | Director | $15,782 | Mixed | 09 Jul 2026 | ||
| Trafford Clarke | Director | $15,761 | Mixed | 09 Jul 2026 | ||
| Mark S. Gelder MD | Chief Medical Officer | $13,847 | Mixed | 13 Mar 2023 | ||
| John H. Leaman | Director | $10,388 | Mixed | 09 Jul 2026 | ||
| TPAV, LLC | 10%+ Owner | $0 | Mixed | 02 Apr 2025 | ||
| Peter Atadja | Director | Mixed | 10 Aug 2023 | |||
| Jerome Groopman | Director | Mixed | 10 Aug 2023 |
Recent insider transactions for Traws Pharma, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Charles D. Pauza | TRAW | Stock Option (right to buy) | Award | 97,000 | 97,000 | 09 Jul 2026 | Direct | |||
| Werner Cautreels | TRAW | Stock Option (right to buy) | Award | 14,150 | 14,150 | 09 Jul 2026 | Direct | |||
| Nikolay Savchuk | TRAW | Stock Option (right to buy) | Award | 93,000 | 93,000 | 09 Jul 2026 | Direct | |||
| Jack E. Stover | TRAW | Stock Option (right to buy) | Award | 14,150 | 14,150 | 09 Jul 2026 | Direct | |||
| Iain D. Dukes | TRAW | Stock Option (right to buy) | Award | 274,000 | 274,000 | 09 Jul 2026 | Direct | |||
| Robert Redfield | TRAW | Stock Option (right to buy) | Award | 84,000 | 84,000 | 09 Jul 2026 | Direct | |||
| Charles N. Parker | TRAW | Stock Option (right to buy) | Award | 90,000 | 90,000 | 09 Jul 2026 | Direct | |||
| Mary Teresa Shoemaker | TRAW | Stock Option (right to buy) | Award | 14,150 | 14,150 | 09 Jul 2026 | Direct | |||
| Trafford Clarke | TRAW | Stock Option (right to buy) | Award | 14,150 | 14,150 | 09 Jul 2026 | Direct | |||
| John H. Leaman | TRAW | Stock Option (right to buy) | Award | 14,150 | 14,150 | 09 Jul 2026 | Direct | |||
| Orbimed Advisors Llc | TRAW | Common Stock | Purchase | 98.7% | $998,207 | $1.67 | 597,729 | 1,203,250 | 16 Apr 2026 | See Footnote |
| Orbimed Advisors Llc | TRAW | Common Stock | Purchase | 98.7% | $998,207 | $1.67 | 597,729 | 1,203,250 | 16 Apr 2026 | See Footnote |
| Orbimed Advisors Llc | TRAW | Series C Warrants (right to buy) | Purchase | 1,793,187 | 1,793,187 | 16 Apr 2026 | See Footnote | |||
| Orbimed Advisors Llc | TRAW | Series C Warrants (right to buy) | Purchase | 1,793,187 | 1,793,187 | 16 Apr 2026 | See Footnote | |||
| Orbimed Advisors Llc | TRAW | Series B Warrants (right to buy) | Purchase | 597,729 | 597,729 | 16 Apr 2026 | See Footnote | |||
| Orbimed Advisors Llc | TRAW | Series B Warrants (right to buy) | Purchase | 597,729 | 597,729 | 16 Apr 2026 | See Footnote | |||
| Orbimed Advisors Llc | TRAW | Series A Warrants (right to buy) | Purchase | 597,729 | 597,729 | 16 Apr 2026 | See Footnote | |||
| Orbimed Advisors Llc | TRAW | Series A Warrants (right to buy) | Purchase | 597,729 | 597,729 | 16 Apr 2026 | See Footnote | |||
| Charles N. Parker | TRAW | Stock Option (right to buy) | Award | 104,544 | 104,544 | 08 Mar 2026 | Direct | |||
| Trafford Clarke | TRAW | Stock Option (right to buy) | Award | 33,435 | 33,435 | 08 Mar 2026 | Direct | |||
| Werner Cautreels | TRAW | Stock Option (right to buy) | Award | 31,258 | 31,258 | 08 Mar 2026 | Direct | |||
| John H. Leaman | TRAW | Stock Option (right to buy) | Award | 33,435 | 33,435 | 08 Mar 2026 | Direct | |||
| Iain D. Dukes | TRAW | Stock Option (right to buy) | Award | 231,336 | 231,336 | 08 Mar 2026 | Direct | |||
| Charles D. Pauza | TRAW | Stock Option (right to buy) | Award | 118,367 | 118,367 | 08 Mar 2026 | Direct | |||
| Nikolay Savchuk | TRAW | Stock Option (right to buy) | Award | 96,899 | 96,899 | 08 Mar 2026 | Direct | |||
| Jack E. Stover | TRAW | Stock Option (right to buy) | Award | 33,435 | 33,435 | 08 Mar 2026 | Direct | |||
| Robert Redfield | TRAW | Stock Option (right to buy) | Award | 108,854 | 108,854 | 08 Mar 2026 | Direct | |||
| Mary Teresa Shoemaker | TRAW | Stock Option (right to buy) | Award | 33,435 | 33,435 | 08 Mar 2026 | Direct | |||
| Charles N. Parker | TRAW | Common Stock | Award | 15,393 | 15,393 | 12 Dec 2025 | Direct | |||
| Charles N. Parker | TRAW | Stock Option (right to buy) | Award | 61,571 | 61,571 | 12 Dec 2025 | Direct | |||
| John Harold Leaman | TRAW | Common Stock | Award | 4,058 | 4,058 | 12 Dec 2025 | Direct | |||
| John Harold Leaman | TRAW | Stock Option (right to purchase) | Award | 16,234 | 16,234 | 12 Dec 2025 | Direct | |||
| Trafford Clarke | TRAW | Common Stock | Award | 6,157 | 6,157 | 12 Dec 2025 | Direct | |||
| Trafford Clarke | TRAW | Stock Option (right to purchase) | Award | 24,629 | 24,629 | 12 Dec 2025 | Direct | |||
| Werner Cautreels | TRAW | Common Stock | Award | 4.67% | 4,874 | 109,222 | 12 Dec 2025 | Direct | ||
| Werner Cautreels | TRAW | Stock Option (right to purchase) | Award | 19,496 | 19,496 | 12 Dec 2025 | Direct | |||
| Mary Teresa Shoemaker | TRAW | Common Stock | Award | 4560.7% | 6,157 | 6,292 | 12 Dec 2025 | Direct | ||
| Mary Teresa Shoemaker | TRAW | Stock Option (right to purchase) | Award | 24,629 | 24,629 | 12 Dec 2025 | Direct | |||
| Jack E. Stover | TRAW | Common Stock | Award | 76962.5% | 6,157 | 6,165 | 12 Dec 2025 | Direct | ||
| Jack E. Stover | TRAW | Stock Option (right to purchase) | Award | 24,629 | 24,629 | 12 Dec 2025 | Direct | |||
| Iain D. Dukes | TRAW | Common Stock | Award | 27.5% | 36,943 | 171,130 | 12 Dec 2025 | Direct | ||
| Iain D. Dukes | TRAW | Stock Option (right to purchase) | Award | 147,771 | 147,771 | 12 Dec 2025 | Direct | |||
| Charles David Pauza | TRAW | Common Stock | Award | 18.9% | 18,471 | 115,971 | 12 Dec 2025 | Direct | ||
| Charles David Pauza | TRAW | Stock Option (right to purchase) | Award | 73,886 | 73,886 | 12 Dec 2025 | Direct | |||
| Robert Redfield | TRAW | Common Stock | Award | 16.8% | 16,419 | 113,919 | 12 Dec 2025 | Direct | ||
| Robert Redfield | TRAW | Stock Option (right to purchase) | Award | 65,676 | 65,676 | 12 Dec 2025 | Direct | |||
| Nikolay Savchuk | TRAW | Common Stock | Award | 12.2% | 16,419 | 150,606 | 12 Dec 2025 | Direct | ||
| Nikolay Savchuk | TRAW | Stock Option (right to purchase) | Award | 65,676 | 65,676 | 12 Dec 2025 | Direct | |||
| John Harold Leaman | TRAW | Stock Option (right to purchase) | Award | 12,770 | 12,770 | 21 Nov 2025 | Direct | |||
| Charles N. Parker | TRAW | Stock Option (right to buy) | Award | 32,406 | 32,406 | 12 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.